Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02772679
Recruitment Status : Active, not recruiting
First Posted : May 13, 2016
Last Update Posted : November 15, 2019
Yale University
Information provided by (Responsible Party):
Jeffrey Bluestone, University of California, San Francisco

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : December 2021